Cytoreductive nephrectomyRenal cell carcinomaSEERSurvivalBackground: We aimed to identify which part of the patients with metastatic renal cell carcinoma (mRCC) is not suitable for cytoreductive nephrectomy (CN). Methods: The data of mRCC patients was acquired from the Surveillance, Epidemiology, and ...
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–70. Article CAS PubMed Google Scholar Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa...
Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma Results from the International Kidney Cancer Working Group 热度: 错配修复基因hM SH2表达与膀胱移行细胞癌预后关系的研究 Relationship between the Expression of hMSH2 and Prognosis in Patients with Bladder Transitional Cell Carcin...
Checkmate 067- advanced melanoma alone or in combination with YERVOY;Checkmate 037 and 066- advanced melanoma;Checkmate 017- squamous non-small cell lung cancer (NSCLC);Checkmate 057- non-squamous NSCLC;Checkmate 025- renal cell carcinoma;Checkmate 205/039- classical Hodgkin lymphoma;...
Long-Term Survival of Patients with Stage T1N0M1 Renal Cell Carcinoma Simple Summary: Localized renal cell carcinoma (RCC) has an excellent prognosis. However, once metastatic, patient prognosis declines significantly. There ... V Schütz,H Lin,A Kaczorowski,... - 《Cancers》 被引量: 0发表:...
Patient Profile Presentation: A 70-Year-Old Man with Stage 4 Clear Cell RCC Author(s): Robert S. Alter, MD,Elan Diamond, MDDr Elan Diamond presents the patient profile of a 70-year-old man with stage IV clear cell renal cell carcinoma. ...
Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib. 2013;35(6):468–76. Woo HK, Park JH, Kang HS, Kim SY, Lee SI, Nam HHJJBC. Charlson comorbidity index as a predictor of long-term survival after ...
Vx-001, which targets the universal tumour antigen TElomerase Reverse Transcriptase (TERT), can mount specific Vx-001/TERT572 CD8 + cytotoxic T cells; this immune response is associated with improved overall survival (OS) in patients with advanced/metastatic non-small cell lung cancer (NSCLC...
” Leighl explained in her oral presentation. “[These patients] had a response rate to the combination of 33% and a median duration of response of 10.9 months. [The combination also produced] very exciting data in patients with renal cell carcinoma and melanoma whose disease...
increased circulating tumour cell adhesion to vascular endothelium of the target organs, surgery-induced angiogenesis transition, surgery-induced immunosuppression and inflammation cascade18,19. However, in other aggressive metastatic cancers, such as ovarian and renal, associations between reduced tumour burde...